One size doesn’t fit all and every patient is unique. Drug compounding is the process of combining, mixing, or altering ingredients to create a medication tailored to the needs of a patient by a pharmacist as the result of a practitioner’s prescription drug order. While compounded medications are not FDA-approved, they serve an important patient need—especially when FDA-approved medication is not available for treatment. Our formulations are made to order in small batches to ensure freshness.

A child who refuses to take medication because of the taste is a prime opportunity for compounding. Children don’t like pills, but they’ll take them gladly when it’s flavored like their favorite fruit or lollipop. Children often cannot take large volumes of liquid medication, but they will accept a small dose of a tasty, fruit-flavored, concentrated solution. By working closely with pediatricians, a compounding pharmacist can prepare medicines in easy-to-give flavored dosage forms that children happily devour.

Patients with food allergies can also be a big challenge for caregivers and practitioners. The foods that most often trigger childhood allergic reactions include eggs, cow’s milk, peanuts, tree nuts, soy, and wheat, and can affect up to 8% of children. Using pharmaceutical-grade ingredients and allergen-free bases, compounding pharmacists can provide a greater variety of medication options. Often, practitioners will turn to their compounding pharmacy to provide critical medications that would otherwise not be available. For example, high-fructose corn syrup and sorbitol, commonly used in commercial medications, must be avoided in children with corn allergies. A compounding pharmacist can choose a solution or suspension base and other ingredients that are free of these allergens.

Most children aged 6–11 years can swallow a small oral tablet with training by a pharmacist or practitioner, but about 9% of children cannot. A compounding pharmacist who is knowledgeable about the pharmaceutical chemistry of each drug can ensure that the patient receives a customized medication that is more likely to be tolerable. Factors such as pH, drug stability, and chemical compatibility are accounted for when deciding on the best delivery vehicle for the medication.

From time to time, a manufacturer may discontinue a veterinary medication. Often this is because it is not needed in the vast quantities necessary to make mass production cost-effective, but that doesn’t mean there aren’t still some pets that need it. When that medication has worked well for animals, a compounding pharmacist can prepare a prescription for the required therapy – and tailor the strength, dosage form, and flavor to that pet’s specific needs.

Sensory processing disorder (SPD) often occurs with developmental disorders, such as autism, fragile X syndrome, and attention-deficit hyperactivity disorder (ADHD). The sensation of taste and texture in the mouth may trigger negative responses in children with this condition. The responses can include gagging, vomiting, and screaming, which will result in non-compliance. Compounding pharmacists have a variety of dosage formulation options, such as capsules, tablets, solutions, suspensions, or even topical preparations. Sometimes modifying the recipe is simple, such as changing the color or using a familiar, favorite flavor to entice a child to accept a medication. Also, children with the sensory disorder tend to be sensitive to gritty textures. In these cases, the compounding pharmacist can reduce the particle size of the medications by grinding in a mortar and pestle so that the mouth feel is smoother for the patient. Suspensions or solutions can also be made in a variety of formulations that have a unique mouth-feel that appeal to the sensitive patient. In other cases, a topical dosage form is applied to the skin. Transdermal administration eliminates the need for oral delivery of the medication. The compounding pharmacist can spend the time with the parents and child to offer choices and options for these children and caregivers when they feel they have none.

1. Compounding and the FDA: Questions and Answers. [(accessed on 23 April 2019)]; Available online: https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/pharmacycompounding/ucm339764.htm

2. Fields J., Go J.T., Schulze K.S. Pill Properties that Cause Dysphagia and Treatment Failure. Curr. Ther. Res. Clin. Exp. 2015;77:79–82. doi: 10.1016/j.curtheres.2015.08.002. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

3. Meltzer E.O., Welch M.J., Ostrom N.K. Pill swallowing ability and training in children 6 to 11 years of age. Clin. Pediatr. 2006;45:725–733. doi: 10.1177/0009922806292786. [PubMed] [CrossRef] [Google Scholar]

4. Baijens L.W., Koetsenruijter K., Pilz W. Diagnosis and treatment of phagophobia: A review. Dysphagia. 2013;28:260–270. doi: 10.1007/s00455-013-9454-0. [PubMed] [CrossRef] [Google Scholar]

5. Webb N.J., Wells T.G., Shahinfar S., Massaad R., Dankner W.M., Lam C., Santoro E.P., McCrary Sisk C., Blaustein R.O. A Randomized, Open-Label, Dose-Response Study of Losartan in Hypertensive Children. Clin. J. Am. Soc. Nephrol. 2014;9:1441–1448. doi: 10.2215/CJN.11111113. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

6. Lacro R.V., Dietz H.C., Sleeper L.A., Yetman A.T., Bradley T.J., Colan S.D., Pearson G.D., Selamet Tierney E.S., Levine J.C., Atz A.M., et al. Atenolol versus Losartan in Children and Young Adults with Marfan’s Syndrome. N. Engl. J. Med. 2014;371:2061–2071. doi: 10.1056/NEJMoa1404731. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

7. Ábarzúa-Araya A., Navarrete-Dechent C.P., Heusser F., Retamal J., Zegpi-Trueba M.S. Atenolol versus propranolol for the treatment of infantile hemangiomas: A randomized controlled study. J. Am. Acad. Dermatol. 2014;70:1045–1049. [PubMed] [Google Scholar]

8. Dai A.I., Aksoy S.N., Demiryürek A.T. Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children with Cerebral Palsy and Spastic Equinus Foot Deformity. J. Child. Neurol. 2016;31:184–189. doi: 10.1177/0883073815587030. [PubMed] [CrossRef] [Google Scholar]

9. Nakano M., Witcher J., Satoi Y., Goto T. Pharmacokinetic Profile and Palatability of Atomoxetine Oral Solution in Healthy Japanese Male Adults. Clin. Drug Investig. 2016;36:903–911. doi: 10.1007/s40261-016-0430-y. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

10. Barst R.J., Beghetti M., Pulido T., Layton G., Konourina I., Zhang M., Ivy D.D. STARTS-2 Investigators. STARTS-2: Long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation. 2014;129:1914–1923. doi: 10.1161/CIRCULATIONAHA.113.005698. [PubMed] [CrossRef] [Google Scholar]

11. AIDSinfo Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. [(accessed on 6 February 2019)]; Available online: https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf

12. CDC Guidelines for the Treatment of Malaria in the United States. [(accessed on 28 February 2019)]; Available online: At http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf

13. Bratzler D.W., Dellinger E.P., Olsen K.M., Perl T.M., Auwaerter P.G., Bolon M.K., Fish D.N., Napolitano L.M., Sawyer R.G., Slain D., et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am. J. Health Syst. Pharm. 2013;70:195–283. doi: 10.2146/ajhp120568. [PubMed] [CrossRef] [Google Scholar]

14. McDonald L.C., Gerding D.N., Johnson S., Bakken J.S., Carroll K.C., Coffin S.E., Dubberke E.R., Garey K.W., Gould C.V., Kelly C., et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) Clin. Infect. Dis. 2018;66:987–994. doi: 10.1093/cid/ciy149. [PubMed] [CrossRef] [Google Scholar]

15. American Academy of Pediatrics . Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. American Academy of Pediatrics; Elk Grove Village, IL, USA: 2015. [Google Scholar]

16. Marco E.J., Hinkley L.B.N., Hill S.S., Nagarajan S.S. Sensory Processing in Autism: A Review of Neurophysiologic Findings. Pediatr. Res. 2011;69:48R–54R. doi: 10.1203/PDR.0b013e3182130c54. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

17. Kirby A.V., Dickie V.A., Bananek G.T. Sensory experiences of children with autism spectrum disorder: In their own words. Autism. 2015;19:316–326. doi: 10.1177/1362361314520756. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

18. Sicherer S.H., Sampson H.A. Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment. J. Allergy Clin. Immunol. 2014;133:291–307. doi: 10.1016/j.jaci.2013.11.020. [PubMed] [CrossRef] [Google Scholar]

19. Liu E., Dong F., Barón A.E., Taki I., Norris J.M., Frohnert B.I., Hoffenberg E.J., Rewers M. High incidence of Celiac Disease in a Long-term Study of Adolescents with Susceptibility Genotypes. Gastroenterology. 2017;152:1329–1336. doi: 10.1053/j.gastro.2017.02.002. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

20. Sansotta N., Amirikian K., Guandalinini S., Jericho H. Celiac disease symptom resolution: Effectiveness of the gluten-free diet. J. Pediatr. Gastroenterol. Nutr. 2018;66:48–52. doi: 10.1097/MPG.0000000000001634. [PubMed] [CrossRef] [Google Scholar]

21. Shah A.V., Serajuddin A.T.M., Mangione R.A. Making all medications gluten free. J. Pharm. Sci. 2018;107:1264–1268. doi: 10.1016/j.xphs.2017.12.021. [PubMed] [CrossRef] [Google Scholar]

22. Kim J.A., Yoon J.R., Lee E.J., Lee J.S., Kim J.T., Kim H.D., Kang H.C. Efficacy of the classic ketogenic and the modified Atkins diets in refractory childhood epilepsy. Epilepsia. 2016;57:51–58. doi: 10.1111/epi.13256. [PubMed] [CrossRef] [Google Scholar]

23. Zupec-Kania B.A., Spellman E. An Overview of the Ketogenic Diet for Pediatric Epilepsy. Nutr. Clin. Pract. 2008;23:589–596. doi: 10.1177/0884533608326138. [PubMed] [CrossRef] [Google Scholar]

24. Arya R., Peariso K., Gaínza-Lein M., Harvey J., Bergin J., Brenton N., Burrows B.T., Glauser T., Goodkin H.P., Lai L.C., et al. Efficacy and safety of ketogenic diet for treatment of pediatric convulsive refractory status epilepticus. Epilepsy Res. 2018;144:1–6. doi: 10.1016/j.eplepsyres.2018.04.012. [PubMed] [CrossRef] [Google Scholar]

25. Strom M.A., Silverberg J.I. Allergic disease is associated with childhood seizures: An analysis of the 1997-2013 National Health Interview Survey. J. Allergy Clin. Immunol. 2016;137:951–953. doi: 10.1016/j.jaci.2015.09.021. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

26. Arnold L.E., Lofthouse N., Hurt E. Artificial food colors and attention-deficit/hyperactivity symptoms: Conclusions to dye for. Neurotherapeutics. 2012;9:599–609. doi: 10.1007/s13311-012-0133-x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

27. Fabiano V., Mameli C., Zuccoti G.V. Paediatric pharmacology: Remember the excipients. Pharmacol. Res. 2011;63:362–365. doi: 10.1016/j.phrs.2011.01.006. [PubMed] [CrossRef] [Google Scholar]

28. Tharp B.R. Neonatal seizures and syndromes. Epilepsia. 2001;43:2–10. doi: 10.1046/j.1528-1157.43.s.3.11.x. [PubMed] [CrossRef] [Google Scholar]

29. Geronzi U., Lotti F., Grosso S. Oxidative stress in epilepsy. Expert Rev. Neurother. 2018;15:427–434. doi: 10.1080/14737175.2018.1465410. [PubMed] [CrossRef] [Google Scholar]

30. Agadi S., Quach M.M., Hanee Z. Vitamin-responsive epileptic encephalopathies in children. Epilepsy Res. Treat. 2013;2013:510529. doi: 10.1155/2013/510529. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

31. DeVivo D.C., Bohan T.P., Coulter D.L., Dreifuss F.E., Greenwood R.S., Nordij D.R., Shields W.D., Stafstrom C.E., Tein I. L-carnitine supplementation in childhood epilepsy: Current perspectives. Epilepsia. 1998;39:1216–1225. [PubMed] [Google Scholar]

32. Coulter D.L. Carnitine deficiency in epilepsy: Risk factors and treatment. J. Child. Neurol. 1995;2:32–39. doi: 10.1177/0883073895010002S05. [PubMed] [CrossRef] [Google Scholar]

33. Heitman T, Day AJ, Bassani AS. Pediatric Compounding Pharmacy: Taking on the Responsibility of Providing Quality Customized Prescriptions. Children (Basel). 2019 May 4;6(5):66. doi: 10.3390/children6050066. PMID: 31060226; PMCID: PMC6560512.

All prescription medications require a valid and complete online consultation prior to approval and final pricing is determined. All compounded medications in the U.S. are considered off-label use. Licensed healthcare practitioners have the ability to prescribe compounds for off-label treatment, if they believe that it is an appropriate course of treatment.

The drug and medical information provided on this website is not meant to cover all adverse effects, drug interactions, warnings, medical uses, directions and precautions. The information provided is a medical resource and the judgment of your physician and/or healthcare practitioner should not be substituted. Premier Pharmacy has made every effort to ensure the information on the website is accurate and current based on present medical literature.

Premier Pharmacy does not make any guarantees regarding the drug and medical information, and does not assume responsibility regarding the content. The drug safety and drug information contained on the website may be time sensitive and should not be utilized as a medical reference beyond the date hereof. The deficiency of a warning for prescription medications and vitamins provided on this website in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient.

If you have questions or concerns about your medications, please do not hesitate to contact us and/or your medical practitioner, including your pharmacist. Compound prescription products have not been tested or approved by the FDA for their intended use. No claims are made as to the safety, efficacy or use of this compound.